Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype

George P. Christophi¹, Michael Panos¹, Chad A. Hudson¹, Rebecca L. Christophi¹, Ross C. Gruber¹, Akos T. Mersich², Scott D. Blystone², Burk Jubelt¹, and Paul T. Massa¹,*

¹Department of Neurology and Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse NY, USA
²Department of Cell and Developmental Biology, SUNY Upstate Medical University, Syracuse NY, USA

Abstract

Recent studies in mice have demonstrated that the protein tyrosine phosphatase SHP-1 is a crucial negative regulator of pro-inflammatory cytokine signaling, TLR signaling, and inflammatory gene expression. Furthermore, mice genetically lacking SHP-1 (me/me) display a profound susceptibility to inflammatory CNS demyelination relative to wild type mice. In particular, SHP-1 deficiency may act predominantly in inflammatory macrophages to increase CNS demyelination as SHP-1-deficient macrophages display co-expression of inflammatory effector molecules and increased demyelinating activity in me/me mice. Recently, we reported that PBMCs of multiple sclerosis (MS) patients have a deficiency in SHP-1 expression relative to normal control subjects indicating that SHP-1 deficiency may play a similar role in MS as to that seen in mice. Therefore, it became essential to examine the specific expression and function of SHP-1 in macrophages from MS patients. Herein, we document that macrophages of MS patients have deficient SHP-1 protein and mRNA expression relative to those of normal control subjects. To examine functional consequences of the lower SHP-1, the activation of STAT6, STAT1, and NF-κB was quantified and macrophages of MS patients showed increased activation of these transcription factors. In accordance with this observation, several STAT6-, STAT1-, and NF-κB-responsive genes that mediate inflammatory demyelination were increased in macrophages of MS patients following cytokine and TLR agonist stimulation. Supporting a direct role of SHP-1 deficiency in altered macrophage function, experimental depletion of SHP-1 in normal subject macrophages resulted in an increased STAT/NF-κB activation and increased inflammatory gene expression to levels seen in macrophages of MS patients. In conclusion, macrophages of MS patients display a deficiency of SHP-1 expression, heightened activation of STAT6, STAT1, and NF-κB and a corresponding inflammatory profile that may be important in controlling macrophage-mediated demyelination in MS.

*Corresponding Author: Mailing Address: Department of Neurology, Upstate Medical University, State University of New York, 750 East Adams Street, Syracuse, NY 13210, Phone Number: (315) 464-7606, Fax: (315) 464-6402, E-mail: massap@upstate.edu.
INTRODUCTION

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system (CNS) that remains a major cause of disability (1). Several studies demonstrated that MS lesions contain multiple leukocyte cell types including lymphocytes, macrophages, and dendritic cells all of which are believed to contribute to lesion formation by various distinct and interacting mechanisms (2, 3). Among these leukocyte subsets, infiltrating macrophages have been identified as major effectors of demyelination in both MS and animal models for MS (4–11). In accord with these studies, it was recently described that a predominant mechanism of demyelination in MS is macrophage–mediated (12).

These findings have stimulated intense interest on the various effector functions of macrophages in lesion formation including signaling events that draw these cells into the CNS white matter and trigger the effector mechanisms by which these cells destroy myelin. For instance, macrophages have been identified as the major responders to CNS chemokines, producers of a number of pro-inflammatory cytokines, chemokines, and toxic molecules known to promote demyelination (7, 13–18), and the major cells involved in phagocytosis/degradation of myelin sheathes. Interestingly, both leukocytes and CNS plaques of MS patients contain activated transcription factors like NF-κB (19, 20), STAT1 (20–22) and STAT6 (23–25), which can lead to enhanced expression of these inflammatory effector functions in macrophages. Based on our previous work, we propose that modulation of inflammatory signaling via these multiple transcriptional pathways may be deficient in leukocytes, including inflammatory macrophages of MS patients, and that this deficiency is responsible for susceptibility to inflammatory demyelinating processes within the CNS.

SHP-1 is a protein tyrosine phosphatase with two SH2 domains which acts as a negative regulator of both innate and acquired immune cytokine signaling via NF-κB (26–28), STAT1 (29, 30), and STAT6 (31–34). Mice genetically lacking SHP-1 (motheaten mice) display myelin deficiency, which may be mediated by increased innate inflammatory mediators in the CNS (35, 36). Furthermore, motheaten mice are highly susceptible to experimentally induced demyelinating disease (37–39). Taken together, these studies indicate that SHP-1 is a key regulator of inflammation in the CNS that may be relevant to the pathogenesis of MS. Indeed, others and we reported that SHP-1 expression and function is deficient in leukocytes of MS patients compared to normal human subjects (22, 25).

We have shown that SHP-1-deficient mice uniquely display an unusually rapid CNS demyelination associated with extensive white matter cellular infiltration and clinical paralysis within the first week of Theiler’s murine encephalomyelitis virus (TMEV) infection compared to their wild type littermates (37). Recently we have shown that SHP-1-deficient mice show a profound and predominant infiltration of blood-derived macrophages into the CNS following TMEV infection and that these macrophages are concentrated to...
areas of demyelination (9). Importantly, these macrophages possessed an inflammatory profile in vivo with an unusual co-activation of STAT6, STAT1, and NF-κB and corresponding responsive pro-inflammatory genes. Because of the rapidity of demyelination in this model, we proposed that SHP-1-deficient macrophages possess a particularly pronounced demyelinating phenotype. Accordingly, macrophage/monocyte depletion with clodronate liposomes resulted in a significant delay in the onset of clinical symptoms and decreased inflammation and demyelination in the spinal cords of SHP-1-deficient mice. Those studies suggested that SHP-1 is an important regulator of CNS inflammatory demyelination acting predominantly to control recruitment of macrophages into the CNS and a broad modulation of macrophage inflammatory effector functions.

In the light of recent studies demonstrating the importance of macrophages in mediating demyelination in MS (12) and our recent studies in SHP-1-deficient mice cited above (9), it became imperative to characterize the inflammatory profile of macrophages of MS patients compared to normal subjects. The present study demonstrates that the expression of SHP-1 is deficient in macrophages of MS patients compared to normal subjects. Corresponding with this deficiency, we show that phosphorylation of STAT6 and STAT1 and activation of NF-κB are higher in macrophages of MS patients compared to those of normal subjects. In accordance with this activation, several STAT6-, STAT1-, and NF-κB-responsive genes that are important for inflammatory demyelination were increased in macrophages of MS patients following cytokine stimulation. Supporting a direct role of SHP-1 deficiency in altered macrophage function, experimental depletion of SHP-1 in macrophages of normal human subjects using siRNA resulted in an increased activation of the above transcription factors and increased inflammatory gene expression to levels seen in macrophages of MS patients. Taken together, we propose the potential involvement of SHP-1 in mediating the augmented inflammatory profile in macrophages seen in MS patients and contributing to the pathogenesis of MS.

MATERIALS AND METHODS

Patient selection

Patients were clinically diagnosed for multiple sclerosis in the SUNY Upstate Medical University MS clinic by established criteria (40). Patients were selected that had not received any disease modifying treatment like IFN-β, glatiramir acetate, steroids or other immunosuppressive agents at least three months prior to donating blood. In this study, macrophage cultures were obtained from 27 patients with relapsing remitting (RR) MS (mean EDSS score of 3.6±1.6) and 24 normal control subjects. The patients and control normal subjects were matched in both age and gender, and the biometric data of the subjects used in this study are shown in Table 1. The Institutional Review Board of SUNY Upstate University approved all studies and both patients and control subjects granted informed consent before providing blood.

Human peripheral blood monocyte-derived macrophages

Patients and normal subjects donated 50 ml of blood collected in heparinazed tubes. Blood was diluted 1:1 with Hank’s balanced salt solution (HBSS) and overlaid onto lymphocyte
separation medium (Cellgro, Herndon, VA). After centrifugation, the 10 ml of the interface containing the PBMCs was collected and washed twice with HBSS. Adherent monocytes were cultured for a week in RPMI media, 15% fetal bovine serum, and 50ng/mL GM-CSF as previously described (41, 42). Medium was replenished every 3 days and non-adherent cells were removed at the second feeding (at 6 days). For experiments, cells were cultured for an additional day in the absence of GM-CSF, washed twice with PBS and adherent cells were lysed in STAT-60 (Tel-Test, Friendswood, TX) for RNA analysis or RIPA buffer (43) for protein analysis. For flow cytometry cells were detached by incubated them in 5.0mM EDTA for 10 minutes at 37 degrees C. The method consistently yielded more than 95% pure macrophages assessed by both morphological criteria as described (44) and expression of the monocyte lineage marker CD14 as determined by flow cytometric analysis.

**Cytokine and siRNA Treatment**

Macrophages of MS patients and normal subjects were cultured for 1 week then GM-CSF was removed from the media. Macrophages were then treated with either 10ng/mL TNF-α, 10 ng/mL of IL-4, 100u/mL IFN-γ (R&D Systems, Minneapolis, MN), 5µg/mL of LPS (Salmonella minnesota re595 LPS; Sigma-Aldrich, St. Louis, MO, USA), 5µg/mL of dsRNA (polyinosinic:polycytidylic acid; Amersham Pharmacia, Piscataway, NJ) or received medium alone for 18hrs.

Anti-SHP-1 siRNA was used to deplete SHP-1 from macrophages of normal subjects. Macrophages were transfected with siRNA against human SHP-1 or scramble siRNA (Dharmacon, Chicago, IL) at a concentration of 1µg/10⁶ cells. The transfection reagent (Dharmafect 4, Dharmacon, Chicago, IL) was used as specified by the manufacturer. Cells were incubated in the transfection medium for 24 hours, after which the medium was replaced with complete growth medium for another 48 hr before cytokine treatment. The effectiveness of the SHP-1 siRNA to lower SHP-1 expression was evaluated by Western immunoblot.

**Real-Time RT-PCR**

Total RNA was isolated using RNA STAT-60. RNA was quantified spectrophotometrically and 0.5 µg of total RNA was converted into cDNA. Briefly, total RNA and random primers (Invitrogen, Carlsbad, CA) were incubated at 72 degrees for 10 minutes. Reverse transcription was performed using the Superscript II RT enzyme (Invitrogen, Carlsbad, CA) and followed the specification of the manufacturer. cDNA was diluted to 200µl with water and 4µl was used for quantitative real-time PCR using SYBR Green kit (Abgene, Epson, UK). The PCR parameters were 15 minutes for 95 degrees and 35 cycles of 95 degrees for 15 seconds and 60 degrees for 1 minute in ABI prism 700 (Applied Biosystems, Foster city, CA). The primers were used at 10 nM. Serial dilutions of cDNA containing a known copy number of each gene were used in each quantitative PCR run to generate a standard curve relating copy number with threshold amplification cycle (45). Gene expression levels were calculated during the logarithmic amplification phase by determining the initial mRNA copy number using the standard curve. Amplification of each specific fragment was confirmed both by examination of melting peaks and by agarose gel electrophoresis. The following primer pairs were used in this study: SHP-1 (BC002523) forward-
Western Blotting

Whole cell extracts were prepared as previously described (26, 30). Briefly, macrophages were rinsed with PBS, and then lysed with RIPA buffer. 10 µg of protein per lane was electrophoresed through a 12.5 % polyacrylamide resolving gel and electroblotted to a polyvinylidene difluoride (PVDF) membrane (Millipore Corporation, Burlington, MA). Membranes were blocked with 5% nonfat dry milk for 1 hour, and then incubated with anti-SHP-1 (Upstate, Lake Placid, NY) antibodies followed by horseradish peroxidase conjugated rabbit IgG antibody. (DAKO Corporation, Carpinteria, CA) or anti-arginase I (BD Biosciences, San Diego, CA) followed by horseradish peroxidase conjugated mouse IgG antibody. Enhanced chemiluminescence (Amersham Life Sciences, Inc., Cleveland, OH) was used to visualize reactive protein bands on X-ray film. Western blot protein bands were quantified based on pixel density using the Scion Image software.

Flow cytometry

For analysis of STAT6 and STAT1 activation, macrophages were treated with either 10ng/mL IL-4, 100 U/mL of IFN-γ, or 10 ng/mL TNF-α, respectively for 1 hour. Cells were then washed twice with PBS and incubated in 5.0 mM EDTA for 10 minutes at 37 degrees C. Cells were detached with gentle pipeting and received 100µL of 16% stock formaldehyde per mL for fixation and then incubated in 90% methanol at 4°C for half an hour to permeabilize cells for intracellular staining. Cells were washed twice with the staining media containing 0.5% BSA and 0.02% sodium azide in PBS. Cells were resuspended in a 100µL of staining media and incubated with 20µL of either phosphoSTAT6 (PY-641) with Alexa-488 (612600), phosphoSTAT1 (PY-701) with Alexa-488 (612596), or mouse IgG with Alexxa-488 isotype control (557721) (Becton Dickinson, Mountain View, CA). In addition, the levels of total (phosphorylated plus unphosphorylated) STAT6 and STAT1 were concurrently analyzed. Fixed and permeabilized cells were incubated overnight at 4°C.
with either 1µg of rabbit anti-total STAT6 (Santa Cruz, CA), rabbit anti-total STAT1 (Upstate Biotechnology, NY), or rabbit polyclonal IgG for isotype control. The cells were incubated for 3 hours in 1µg of goat anti-rabbit secondary antibody conjugated to PE (Invitrogen, Carlsbad, CA).

Furthermore, fixed and permeabilized cells were incubated overnight at 4°C with either 1µg of rabbit anti-SHP-1 (Upstate, Lake Placid, NY) or rabbit polyclonal IgGs for isotype control. The cells were incubated for 3 hours in 1µg of goat anti-rabbit secondary antibody conjugated to PE (Invitrogen, Carlsbad, CA). In addition several extracellular markers were quantified by flow cytometry. 5×10^5 Cells were incubated in 15µL of CD14-APC, CD11b-FITC, CD49d-PE, or CCR2-APC (Becton Dickinson, Mountain View, CA) for 1 hour at room temperature. Cells were analyzed on an LSRII analyzer (Becton Dickinson, Mountain View, CA) and the mean florescence intensity (MFI) was recorded.

**NF-κB DNA-binding activity assay**

NF-κB DNA-binding activity was analyzed using the TransAM NF-κB p65 transcription factor assay kit (Active Motif, Carlsbad, CA) following the manufacturer’s instructions and as previously described (46–48). Briefly, nuclear extracts were prepared (26) from macrophages of normal subjects and MS patients that were treated with media alone or 20 ng of TNF-α or 5µg/mL of LPS for 1 hour. Protein levels of the nuclear extracts were quantified with the Bradford assay (Pierce Chemicals, Rockford, IL) and 10 µg were incubated in a 96-well plate coated with oligonucleotide containing the NF-κB consensus-binding sequence 5’-GGGACTTTCC-3’. Bound NF-κB was then detected by a p65-specific primary antibody. An HRP-conjugated secondary antibody was then applied to detect the bound primary antibody and provided the basis for colorimetric quantification. The enzymatic product was measured at 450 nm with a reference wavelength of 650 nm by a microplate reader. To quantify the amount of NF-κB, serial dilutions of purified p65 recombinant protein (20ng - 0.16ng) were measured to provide a calibration curve between p65 binding and absorbance. The specificity of the assay was further tested by the addition of wild type or mutated NF-κB consensus oligonucleotide in the competitive or mutated competitive control wells before the addition of nuclear extracts. The addition of the wild-type NF-κB consensus oligonucleotide completely abolished NF-κB binding.

**Cytokine ELISA**

The levels of the cytokines TNF-α and IL-6 were measured using R&D Systems DuoSet ELISA kits (R&D Systems, Minneapolis, MN) following the manufacturer’s protocol.

**Nitric Oxide Assay**

The amount of NO produced was measured in amounts of nitrite in macrophage supernatants. Macrophages from normal subjects and MS patients were treated with either media alone, TNF-α, IL-4, IFN-γ, or LPS for 18hrs and supernatants were mixed with the Greiss reagent at a 1:1 ratio (Sigma, St. Louis, MO). The reaction was allowed to proceed for 15 min, at which time the absorbance at 540nm was quantified with an ELISA plate reader. A calibration curve was generated using sodium nitrite (1–100µM) and used to calculate the amount of nitrite present in macrophage supernatants.
Arginase Activity Assay

Arginase enzymatic activity was measured as previously described (31, 49). Briefly, cultured macrophages were lysed in RIPA buffer and incubated in 10 mM MnCl$_2$ and 0.5 M L-arginine at 37°C for 75 min. After the assay was stopped by addition of H$_3$PO$_4$, 1-phenyl-1,2-propanedione-2-oxime (Sigma, St Louis, MO) was added and the samples were incubated at 100°C for 60 min. Urea production by arginase was measured by optical density at 540 nm.

Statistical Analysis

Histograms contain statistical means with the standard error values. Unless otherwise specified, 27 samples from MS patients and 24 samples from normal subjects were used. In the SHP-1 siRNA experiments samples of macrophages from 15 normal human subjects were used. The p-values were generated using the unpaired Student’s t-test and p-values between groups are displayed on histograms. A p-value of less than 0.05 was chosen to indicate statistical significance between two sample means.

RESULTS

Characterization of adhesion/activation molecules in blood-derived macrophages of MS patients and normal subjects

The expression levels of multiple macrophage markers were quantified by flow cytometry in cultured macrophages of normal subjects and MS patients (Figure 1). More than 95% of the cells stained for CD14 and no significant differences in levels of expression were observed between the subject groups (Figure 1A). Furthermore, we examined the expression of CCR2 (CD192), which is the receptor for the chemokine MCP-1 and a marker for inflammatory monocytes (50). Importantly, macrophages of SHP-1 deficient mice display increased levels of CCR2 (51, 52). Macrophages of MS patients had significantly higher levels of CCR2 compared to normal subjects indicating that MS-derived macrophages have a relatively heightened inflammatory state. As such, we characterized two other potential activation markers on these cells. We analyzed the antigenic determinants of CD11b ($\alpha$M$\beta$2 integrin) and VLA4 ($\alpha$4$\beta$1 integrin), which have been shown to be important in the trafficking, adhesion, phagocytosis, and migration of macrophages at inflammatory sites (53–56). Integrin $\alpha$M$\beta$2 expression was significantly higher in the macrophages of MS patients compared to normal subjects. In contrast, the expression of integrin $\alpha$4$\beta$1 was not significantly different between macrophages of MS patients and normal subjects.

SHP-1 Protein and mRNA are lower in macrophages of MS patients

We have previously described that PBMCs of MS patients have decreased expression of SHP-1 compared to normal subjects (25). Cultured macrophages of MS patients had significantly lower levels of SHP-1 protein than those of normal subjects measured by intracellular flow cytometry (Figure 2A & 2B). To corroborate these findings, the levels of SHP-1 protein in macrophages were measured by western immunoblotting (Figure 2C). On average, SHP-1 levels in macrophages of MS patients were half the levels of SHP-1 in cells of normal subjects.
To examine whether macrophages of MS patients displayed a deficiency in SHP-1 at the transcriptional level, the levels of SHP-1 mRNA were quantified using primers flanking the coding region of the gene common to both transcripts (Figure 3). SHP-1 mRNA levels in macrophages were significantly lower in MS patients compared to normal subjects (Figure 3A). Furthermore, analysis of SHP-1 mRNA expression in individual subject groups did not show any statistically significant correlation between either age or gender and SHP-1 levels (data not shown).

**SHP-1 promoter II transcripts are selectively lower in MS patients**

In order to determine the individual contribution of each of two known transcripts on the expression levels of SHP-1 in macrophages, promoter I and II transcript copy numbers were measured using promoter-specific RT-PCR primers. Constitutive levels of SHP-1 promoter I transcripts were not significantly lower in macrophages in MS patients compared to controls (Figure 3C). On the other hand, constitutive levels of SHP-1 promoter II transcripts were significantly lower in macrophages of MS patients compared to controls (Figure 3D). Taken together, we concluded that macrophages of MS patients have constitutively lower levels of SHP-1 protein and mRNA compared to normal subjects and furthermore that a lack in promoter II transcripts is primarily responsible for this deficiency.

**Analysis of STAT6 and STAT1 activation in MS macrophages**

SHP-1 regulates phosphorylation of several STATs by enzymatic removal of the phosphate group from tyrosine either on activated cytokine receptors or downstream signaling molecules. Thus, SHP-1 modulates STAT activation, translocation into the nucleus, and transcriptional activity on responsive genes. Because several studies showed that SHP-1 stringently modulates IL-4Rα/STAT6 signaling molecules (31, 32, 34, 57), and STAT6 was shown to be elevated in MS (23–25), we examined STAT6 activation in macrophages from MS patients (Figure 4). For analysis, we measured the level of total STAT6 (unphosphorylated plus phosphorylated) and tyrosine phosphorylated STAT6 (pSTAT6) in macrophages using intracellular flow cytometry. As expected, macrophages of MS patients had significantly elevated constitutive phosphorylation of STAT6 compared to macrophages of normal subjects (Figure 4B). In contrast, there were no differences in the expression levels of total STAT6 protein (Figure 4A), verifying that the differences observed in pSTAT6 levels are attributed to the relative phosphorylation state of STAT6. Staining the same cells for SHP-1 revealed a reciprocal expression pattern of SHP-1 and pSTAT6, such that lower constitutive levels of SHP-1 in MS patients correlated with higher pSTAT6 levels compared to macrophages of normal subjects (data 18 not shown). Furthermore, macrophages were treated for 1 hour with IL-4, which induces phosphorylation of STAT6, to determine possible differences in STAT6 activation following engagement of the IL-4 receptor. Treatment with IL-4 caused higher phosphorylation of STAT6 in macrophages of MS patients compared to normal subjects (Figure 4B). Similar results were obtained when macrophages were treated with IL-13, another cytokine that mediates STAT6 activation via the IL-4Rα (data not shown).

Apart from STAT6, there are several other transcription factors that are elevated in MS patients and are controlled by SHP-1. In particular, tyrosine phosphorylated STAT1 (pY-
STAT1) that mediates interferon signaling was found to be elevated in MS patients (20, 21) and is controlled by SHP-1 (29, 30, 58, 59). Therefore, we characterized STAT1 activation by measuring the level of total STAT1 (unphosphorylated plus phosphorylated, STAT1) and tyrosine phosphorylated STAT1 (pSTAT1) in macrophages using intracellular flow cytometry. No differences were observed in total STAT1 protein (Figure 4C). Constitutive pSTAT1, although higher, was not significantly elevated in macrophages of MS patients compared to normal subjects (Figure 4D). However, 1 hour treatment with IFN-γ resulted in higher phosphorylation of STAT1 in macrophages of MS patients compared to normal subjects (Figure 4D). Taken together this data suggest that both STAT6 and STAT1 show enhanced cytokine-mediated activation in macrophages of MS patients, in accordance with SHP-1 deficiency relative to normal subject macrophages.

**Elevated expression of NF-κB DNA-binding activity and TNF-α/IL-6 secretion in macrophages of MS patients**

Another important transcription factor involved in the pathogenesis of MS is NF-κB (19, 60). Notably, NF-κB activation was observed in inflammatory macrophages in MS CNS lesions (61). Several reports have documented the negative regulation of NF-κB by SHP-1 (26, 27, 59, 62, 63). Therefore, it was important to examine NF-κB activation in macrophages of MS patients (Figure 5A). Macrophages from normal subjects and MS patients were treated with medium alone, TNF-α or LPS and then nuclear extracts were isolated and allowed to bind an NF-κB consensus oligonucleotide sequence. Bound NF-κB was then detected by a p65 (RelA)-specific antibody and quantified based on a calibration curve generated by using a purified p65 recombinant protein. Constitutively, NF-κB binding was slightly, but significantly elevated in macrophages of MS patients compared to normal subjects (Figure 5A). Furthermore, treatment with either TNF-α or LPS dramatically increased NF-κB binding and importantly nuclear extracts from macrophages of MS patients showed significantly increased binding compared to macrophages of normal subjects.

In addition, we quantified the secretion of the NF-κB-responsive pro-inflammatory cytokines TNF-α and IL-6 from macrophages of MS patients compared to normal subjects, since it was previously shown that a deficiency in SHP-1 leads to higher expression of these cytokines (9, 27, 62, 64–66). Macrophages were cultured for 18 hours with either media alone, TLR ligands or TNF-α and the supernatants were analyzed for the presence of TNF-α or IL-6 (Figure 5B & 5C). Constitutively, the levels of TNF-α and IL-6 were slightly but significantly elevated in supernatants of macrophages from MS patients compared to normal subjects. Furthermore, stimulation of macrophages with LPS or dsRNA resulted in a substantial induction of TNF-α and IL-6 in both subject groups but the induction was significantly higher in macrophages of MS patients compared to normal subjects. In all, these data demonstrate that macrophages of MS patients display an enhanced expression of NF-κB-responsive genes both constitutively and after stimulation with TLR ligands and cytokines that induce NF-κB.
**Heightened expression of STAT6-, STAT1-, and NF-κB-responsive genes in MS macrophages**

In order to determine whether increased activation of STAT6, STAT1, and NF-κB in macrophages of MS patients relative to normal subjects corresponded to heightened expression of STAT6-, STAT1-, and NF-κB responsive genes, the mRNA levels of several genes were quantified following 18-hour treatment with several cytokines (Figure 6). The expression levels of STAT6-responsive chemokines were of particular interest because these mediate trafficking, maturation, and attraction of lymphocytes and macrophages to areas of CNS inflammation (14). CCL17/TARC (67, 68) and CCL11/Eotaxin I (69) were substantially induced in macrophages following IL-4 treatment and importantly macrophages of MS patients showed significantly higher induction compared to macrophages of normal subjects (Figure 6A & 6B). Similar results were obtained when macrophages were treated with IL-13 (data not shown). Similarly, the mRNA of ADAM8, a STAT6-responsive disintegrin matrix metalloproteinase (70, 71) that may be involved in demyelination (72), was induced at higher levels in macrophages of MS patients compared to macrophages of normal subjects following IL-4 treatment (data not shown). Taken together, in agreement with depressed SHP-1 levels, macrophages of MS patients display increased STAT6 activation and increased expression of STAT6-responsive gene expression.

Furthermore, because SHP-1 controls STAT1 activation (29, 30, 58, 73), we examined the expression of STAT1-responsive genes following cytokine stimulation (Figure 6). The chemokine IP-10, a STAT1-inducible chemokine that was previously shown to be elevated in MS (74–78), was highly induced by IFN-γ and moderately induced by LPS in MS macrophages. Moreover, IP-10 was induced to significantly higher levels in MS macrophages compared to normal subject macrophages (Figure 6C). Similarly, caspase 1, a STAT1-inducible enzyme involved in IL-1β-mediated inflammation (79–81), was significantly induced to higher levels by IFN-γ in MS macrophages compared to macrophages of normal subjects (Figure 6D). These data suggest that STAT1 phosphorylation and STAT1-responsive genes show enhanced activation in macrophages of MS patients compared to macrophages of normal subjects.

Moreover, since NF-κB binding was elevated in macrophages of MS patients, we wanted to examine whether NF-κB-responsive genes were elevated in macrophages of MS patients. Therefore, we quantified the expression of the NF-κB inducible chemokine MCP-1 and cyclooxygenase-2 (COX-2) (82, 83) with real time RT-PCR (Figure 6E & 6F). MCP-1 and COX-2 genes showed substantially higher induction in macrophages of MS patients compared to normal subjects following treatment with either TNF-α or LPS. These data further demonstrate that NF-κB activation and NF-κB-responsive genes are elevated in macrophages of MS patients compared to normal subjects.

**Arginase I and iNOS expression and activity are enhanced in macrophages of MS patients**

Several reports in mouse models point to the importance of different macrophage activation profiles in specific types of inflammatory disease (84). Recently characterized macrophage profiles are the classically activated (or M1 macrophages) that display increased
STAT1/NF-κB-responsive genes including inducible nitric oxide synthase (iNOS) and alternatively activated (or M2 macrophages) that display increased STAT6-responsive genes including arginase I. Interestingly, there is usually a profound antagonism of differentiation towards either M1 or M2 macrophage activation profile such that dual expression of iNOS and arginase I is seldomly observed (85–88). Using this paradigm, we determined whether MS macrophages might be preferentially skewed toward either the M1 or M2 profile relative to those of normal subjects.

Examination of constitutive iNOS mRNA expression and nitric oxide (NO) production showed no differences between MS and normal subject macrophages (Figure 7). TNF-α and IFN-γ moderately and LPS substantially induced iNOS mRNA expression and NO production in macrophages (Figure 7A & 7B). Importantly, macrophages from MS patients showed a significantly higher iNOS mRNA expression and NO production following cytokine stimulation compared to macrophages from normal subjects. With respect to constitutive arginase I expression, we found higher levels of both arginase I protein, mRNA, and enzymatic activity in MS compared to normal subject macrophages (Figure 6C–E). Moreover, when macrophages were exposed to M2-inducing cytokine IL-4, MS macrophages expressed more arginase I than normal subject macrophages. These data indicated that MS macrophages may be constitutively skewed towards M2 activation profile in vitro and this skewing may be further reinforced by IL-4. Nonetheless, MS macrophages also display M1-skewedness relative to normal subject macrophage following exposure to M1-inducing cytokines such as IFN-γ and TNF-α. The latter indicates the extreme plasticity of MS macrophages relative to normal subject macrophages and the potential importance of the cytokine milieu in determining the ultimate balance between M1 and M2 phenotype of these cells.

SHP-1 depletion in normal subject macrophages enhances their inflammatory profile

To examine whether decreased SHP-1 levels are directly responsible for transcription factor activation and inflammatory gene expression in macrophages, macrophages of normal subjects were treated with siRNA to acutely deplete SHP-1 (Figure 8). First, we observed that SHP-1 protein was substantially depleted by more than 5-fold in the macrophages treated with the SHP-1 siRNA compared to the macrophages treated with control siRNA of scrambled sequence (Figure 8A). Accordingly, SHP-1 depletion resulted in a considerable increase of the STAT6-responsive arginase I protein (Figure 8A) and mRNA (data not shown).

Further, we investigated whether lowered SHP-1 levels in normal human macrophages treated with siRNA led to enhanced activation of STAT6 and STAT1. SHP-1 depletion resulted in a significant increase in constitutive STAT6 phosphorylation and to a significantly higher induction of pSTAT6 in response to 1-hour treatment with IL-4 (Figure 8B). Similar results were obtained when macrophages were treated with IL-13, another cytokine that mediates STAT6 activation via the IL-4Rα (data not shown). In addition, although SHP-1 depletion did not result in a significant increase of constitutive STAT1 phosphorylation, IFN-γ treatment for 1 hour induced significantly higher pSTAT1 levels in SHP-1 depleted macrophages compared to control macrophages treated with scrambled
siRNA (Figure 8C). To further validate that SHP-1 controls STAT6 and STAT1 activation, we examined the expression of STAT6- and STAT1-responsive genes in macrophages of normal subjects that were treated with either scramble siRNA or SHP-1 siRNA. The STAT6-inducible genes CCL17 (Figure 8D), Arginase I, CCL11, and ADAM8 (data not shown) were significantly induced to higher levels in SHP-1-depleted macrophages following an 18-hour IL-4 stimulation. Similarly, the STAT1-inducible genes IP-10 (Figure 8E) and caspase 1 (data not shown) were induced at significantly higher levels in SHP-1-depleted macrophages following IFN-γ treatment. Taken together, these results point to the important role of SHP-1 in down-modulating pro-inflammatory STAT6 and STAT1 activities in human macrophages.

Furthermore, we examined the role of SHP-1 in controlling NF-κB-responsive genes in human macrophages. First mRNA levels of the NF-κB-inducible chemokine MCP-1 (Figure 8F) and COX-2 (data not shown) were induced at significantly higher levels in SHP-1-depleted macrophages following TNF-α or LPS treatment. Furthermore, the secretion of TNF-α and IL-6 in SHP-1-depleted macrophages was significantly higher following LPS or dsRNA stimulation compared to macrophages treated with scramble siRNA (Figure 8G & 8H). Additionally, TNF-α or LPS treatment led to a significantly higher production of NO in SHP-1-depleted macrophages compared to macrophages treated with scramble siRNA (Figure 8I). Taken together, we concluded that depressed levels of SHP-1 in human macrophages led to a unique co-activation of STAT6/STAT1/NF-κB-responsive pro-inflammatory genes relative to normal subject macrophages. With the observation of heightened CCR2 (Figure 1), we propose that MS macrophages may be inherently inflammatory in nature.

**DISCUSSION**

In multiple sclerosis and animal models for MS, intense macrophage infiltration is present in active demyelinating lesions and both their numbers and differentiation/activation correlates with disease severity (2, 4, 5, 89, 90). Macrophages can mediate myelin phagocytosis, degradation, oligodendrogliopathy, and axonal loss both through cell-mediated processes and the secretion of inflammatory mediators (1, 7, 90, 91). Based on our recent report of increased demyelinating activity of macrophages in me/me mice (9), a key question was whether macrophages of MS patients display similar defects in modulation of pro-inflammatory cytokine signaling that may contribute to activated inflammatory profile and demyelinating activity.

Therefore, we analyzed the expression and function of SHP-1 as a possible cause of enhanced macrophage inflammatory activity in MS. Examining monocyte-derived macrophages from MS patients and normal subjects revealed that SHP-1 was deficient in macrophages of MS patients. Interestingly, this SHP-1 deficiency corresponded to a diminished expression of SHP-1 promoter II transcripts suggesting a specific alteration in promoter II function in MS. Accordingly, macrophages from MS patients displayed enhanced STAT6, STAT1, and NF-κB activity, transcription factors that were previously shown to be modulated by SHP-1 in various cell types including mouse macrophages (9). In turn, several STAT6-, STAT1-, and NF-κB-inducible genes that have been shown to play
role in the mechanism of inflammatory demyelination were shown to be both higher in macrophages of MS patients and regulated by SHP-1.

The relevance of the present findings to the pathogenetic mechanisms of MS is supported by previous reports on activation of signaling molecules in the CNS of MS subjects that are regulated by SHP-1. For instance, phosphorylated STAT6 was found to be highly expressed in MS lesions (24), normal appearing white matter of MS patients (23) and leukocytes of MS patients (25). Furthermore, macrophages of mice that lack SHP-1 show increased constitutive activation of STAT6 and heightened levels of STAT6-inducible genes (25). Moreover, the lack of SHP-1 leads to severe macrophage-mediated CNS demyelination following TMEV infection (9, 31, 37). Thus, the present study suggests that STAT6 activation and expression of several genes with confirmed STAT6-responsive elements in macrophages may have functional significance to the pathophysiology of MS. For example, the chemokines CCL17/TARC and CCL11/Eotaxin, which attract inflammatory cells to demyelinating lesions, were elevated in macrophages of MS patients and the expression of these chemokines is controlled by SHP-1 (92–94).

Analysis of other STAT6-responsive genes showed that the matrix metalloproteinase ADAM8 is elevated in macrophages of MS patients and SHP-1 controls its expression. Proteinases may be involved in the pathogenesis of MS, since these can mediate the proteolysis of extracellular matrix molecules, disrupt the blood brain barrier, and promote leukocyte entry into the brain parenchyma (95). ADAM8 which is highly expressed in macrophages was shown to hydrolyze myelin basic protein (72) and can therefore directly contribute to demyelination. In addition, arginase I is a STAT6-responsive gene that has been shown to be constitutively elevated in the CNS of SHP-1-deficient mice and plays an important role in virus-induced demyelinating disease (31). Also, arginase I inhibition results in attenuation of EAE onset and progression (73). Interestingly, the increased levels of arginase I in MS macrophages might make these cells more susceptible to viral infections relevant to MS pathogenesis (31). Although the mechanism by which arginase I activity may promote inflammatory demyelination still remains to be elucidated, its role in MS in light of the present findings should be further investigated.

Apart from STAT6, there are several other transcription factors that were previously shown to be elevated in MS patients and are controlled by SHP-1. In particular, tyrosine phosphorylated STAT1 (pY-STAT1) that mediates interferon signaling was found to be elevated in MS patients and controlled by SHP-1 (20–22, 30, 58). In agreement with those studies, we found that STAT1 activation is enhanced in macrophages of MS patients following IFN-γ stimulation. Furthermore, STAT1-inducible genes like the chemokine IP-10 and caspase 1 are elevated in macrophages of MS patients consistent with a role for STAT1 in expression of these genes (74–79, 96). Thus, lower levels of SHP-1 seen in macrophages of MS patients may lead to activation of STAT1 and STAT1-inducible genes that play a role the pathogenesis of MS.

Furthermore, the transcription factor NF-κB mediates pro-inflammatory cytokine signaling and is elevated in MS PBMCs (19) and macrophages in MS lesions (60, 61). Thus, it may be important that mice genetically lacking SHP-1 show elevated NF-κB activity and increased
NF-κB inducible genes in both CNS glia and hematopoietic cells (9, 26, 27, 59, 94). Therefore it was imperative to investigate whether NF-κB-responsive genes were elevated in macrophages of MS patients. Both the chemokine MCP-1 and COX-2 showed significantly elevated induction in macrophages from MS patients compared to normal subjects reflecting the increased NF-κB binding activity observed in MS macrophages. In addition, the inflammatory cytokines TNF-α and IL-6, which are regulated by NF-κB, were secreted at higher levels in macrophages of MS patients compared to macrophages of normal subjects following LPS or dsRNA stimulation which signal via TLR4 and TLR3 respectively to activate NF-κB.

Considering that SHP-1-depleted macrophages of normal subjects display a very similar inflammatory profile to macrophages of MS patients, it is likely that the deficiency of SHP-1 seen in macrophages of MS patients is directly responsible for the increased inflammatory profile. As such, the classification of macrophage phenotypic markers may be an important consideration in MS. Several reports in mouse models point to the importance of different macrophage activation profiles in specific types of inflammatory disease (84). For instance, so-called classically activated or M1 macrophages display increased STAT1- and NF-κB-responsive genes, which have been shown to be critical for eradicating various intracellular microbes and causing some types of autoaggressive tissue inflammation such as rheumatoid arthritis. Conversely, so-called “alternatively activated” or M2 macrophages display increased STAT6-responsive genes including arginase I and may be more important for eradicating helminthes and promoting allergic-type inflammatory diseases. Importantly, there is usually a profound antagonism between differentiation towards either M1 or M2 macrophage activation profiles such that dual expression of M1 and M2 genes are rarely seen. In possible distinction to these prior classifications, the present study indicates that macrophages of MS patients may exhibit abnormally high activation of either STAT6, STAT1 or NF-κB, depending on the nature of cytokine stimulation. As such, a deficiency in SHP-1 may allow an aberrant co-activation of STAT6/STAT1/NF-κB responsive genes in MS macrophages especially in vivo where these cells may be simultaneously exposed to both M1- and M2-skewing cytokines. If so, the inflammatory nature of these macrophages may be unique and perhaps possess a corresponding enhanced demyelinating capacity.

Such a concurrent activation of normally opposed pathways in MS macrophages is supported by observations of patterns of gene expression in leukocytes including macrophages in MS, where increased co-expression of STAT6/STAT1/NF-κB-responsive genes is observed (20, 21, 24, 25). Adding to the promotion of broad activation phenotype of macrophages in MS are reports showing that high levels of both Th1 and Th2 cytokines are co-expressed in MS. For instance, cultured myeloid dendritic cells from RR MS patients polarize naïve T-cells to both Th1 and Th2 and induce increased levels of IFN-γ, IL-4/IL13, and TNF-α (97, 98). In accord with these findings, several studies demonstrate that plasma, leukocytes, and CSF of patients with active MS show a concurrent increase of IFN-γ, IL-4/IL13, and TNF-α levels compared to normal subjects (99–107).

The high levels of plasma cytokines certainly contributes to the enhanced transcription factor activation previously observed in freshly isolated peripheral blood cells of MS patients (19, 21, 22). In distinction to these prior studies, the present study exclusively
employs cultured macrophages of MS patients and normal subjects, which offers the advantage of allowing stimulation of the cells with equal amounts of the cytokines IFN-γ, IL-4, and TNF-α and therefore examining intrinsic differences in cytokine signaling. Therefore, apart from the elevated cytokine levels that are observed in MS patients, this study further documents that macrophages of MS patients display enhanced signaling in response to both Th1 and Th2 pro-inflammatory cytokines and therefore the lack of SHP-1 may be responsible for a broad inflammatory profile of these cells.

Another question that arises is how the SHP-1 deficiency observed in peripheral macrophages of MS patients might only be manifested as CNS inflammatory demyelination in MS patients. One possibility is that persistent CNS viruses might attract macrophages into the CNS and the lower levels of SHP-1 in MS macrophages enhance migration to and demyelinating activity with the CNS. The latter is supported by studies showing that TMEV infection in SHP-1-deficient mice results in severe CNS demyelination that is exclusively macrophage-mediated (108). Furthermore, deficiency of SHP-1 in macrophages enhances responsiveness to chemokines including MCP-1 that play an important role in macrophage-mediated demyelination (9, 51). Another possibility is that macrophages are attracted into the CNS through myelin-specific autoimmune events. Once macrophages enter the CNS, the SHP-1-deficiency can contribute to enhanced Fc-gamma receptor mediated myelin phagocytosis in the presence of antibodies and complement (12, 109–111). These hypotheses indicate a two-step process in which SHP-1-deficiency in macrophages is a precondition to tissue specific inflammation triggered by a CNS specific inflammatory signal. The latter is consistent with a recent mouse study in which SHP-1 deficiency alone does result in inflammatory disease but rather establishes a permissive state in which microbial infection triggers inflammation and autoimmunity (28).

Two distinct promoters drive the expression of two different SHP-1 transcripts from the SHP-1 gene (112–114). Here, we demonstrated that promoter II transcripts, which are preferentially expressed in hematopoietic cells, are selectively lower in macrophages of MS patients compared to normal subjects. The question thus arises as to the potential genetic basis for deficient SHP-1 promoter II activity in MS leukocytes. Several studies have examined the contribution of genetics in MS (115–118) and with exception to some weak association in some populations, no study has shown an absolute linkage to the SHP-1 locus, chromosome 12p12 (119) that would explain a wide-spread deficiency in promoter II expression in MS patients. As such, alternative mechanisms need to be considered including epigenetic alterations in promoter activity. Indeed, numerous reports document the down-regulation of SHP-1 promoter II transcripts in leukemia/lymphoma cell lines and attribute SHP-1 deficiency to epigenetic methylation of particular CpG sites of SHP-1 promoter II (120, 121). Interestingly, in the context of MS, either viral infections (122–127) or inflammation (128–131) can cause de novo methylation or hypermethylate CpG promoter sequences resulting in decreased gene expression. Furthermore, a recent studies report that HTLV-1, which has been associated with the CNS demyelinating disease known as HAM/TSP (HTLV-1 associated myelopathy/Tropical Spastic Paparparesis) (132), profoundly and specifically suppresses SHP-1 expression through methylation of the SHP-1 promoter II (133, 134). In accordance with these reports, preliminary data indicate that treatment of PMBCs of MS patients with the demethylating agent 2′-deoxy-5-azacytidine

Lab Invest. Author manuscript; available in PMC 2010 January 01.
increase SHP-1 promoter II transcripts to normal levels (personal unpublished observations). Whether a stable epigenetic modification of promoter II or another mechanism results in a deficiency in SHP-1 expression in macrophages from MS patients requires further investigation.

ACKNOWLEDGEMENTS

We would like to thank Dr. Isobel Scarisbrick at Mayo Clinic for providing cDNA plasmids used in performing real time RT-PCR. We thank Carol Ozark for collection of normal subject blood samples. We would also like to thank Dr. Nick J. Gonchoroff, for his expertise in flow cytometry/cell sorting performed in this study.

References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000; 343(13):938–952. [PubMed: 11006371]
2. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707–717. [PubMed: 10852536]
3. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull. 2003; 61(3):321–326. [PubMed: 12909302]
4. Bruck W, Sommermeier N, Bergmann M, Zettl U, Goebel HH, Kretzschmar HA, et al. Macrophages in multiple sclerosis. Immunobiology. 1996; 195(4–5):588–600. [PubMed: 8933159]
5. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol. 2001; 159(5):1701–1710. [PubMed: 11696431]
6. Lipton HL, Kumar AS, Trottier M. Theiler's virus persistence in the central nervous system of mice is associated with continuous viral replication and a difference in outcome of infection of infiltrating macrophages versus oligodendrocytes. Virus Res. 2005; 111(2):214–223. [PubMed: 15893838]
7. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev. 2005; 48(2):185–195. [PubMed: 15850657]
8. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med. 1997; 75(3):165–173. [PubMed: 9106073]
9. Christophi GP, Hudson CA, Panos M, Gruber R, Massa PT. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol. 2008
10. Templeton SP, Kim TS, O'Malley K, Perlman S. Maturation and localization of macrophages and microglia during infection with a neurotropic murine coronavirus. Brain Pathol. 2008; 18(1):40–51. [PubMed: 17935605]
11. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol. 1998; 92(1–2):38–49. [PubMed: 9916878]
12. Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008; 63(1):16–25. [PubMed: 18232012]
13. Dogan RN, Karpus WJ. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front Biosci. 2004; 9:1500–1505. [PubMed: 14977561]
14. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006; 27(1):48–55. [PubMed: 16310865]
15. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 2007; 17(2):219–229. [PubMed: 17388953]
16. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem. 2008; 389(6):739–745. [PubMed: 18627300]
17. Scarisbrick IA, Blaber SI, Lucchietti CF, Genain CP, Blaber M, Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain. 2002; 125(Pt 6):1283–1296. [PubMed: 12023317]
18. Karpus WJ, Kennedy KJ, Fife BT, Bennett JL, Dal Canto MC, Kunkel SL, et al. Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol. 2006; 12(4):251–261. [PubMed: 16966216]
19. Eggert M, Goertsches R, Seeck U, Dilk S, Neeck G, Zettl UK. Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J Neurol. 2008; 264(1–2):145–150. [PubMed: 17889033]
20. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, De Groot CJ. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia. 2001; 36(1):68–77. [PubMed: 11571785]
21. Frisullo G, Angelucci F, Caggiula M, Nociti V, Iorio R, Patanella AK, et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci. 2006; 84(5):1027–1036. [PubMed: 16865709]
22. Feng X, Petraglia AL, Chen M, Bykskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002; 129(1–2):205–215. [PubMed: 12161037]
23. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain. 2008; 131(Pt 1):288–303. [PubMed: 18056737]
24. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol. 2004; 55(1):46–57. [PubMed: 14705111]
25. Christophi GP, Hudson CA, Gruber RC, Christophi CP, Mihai C, Mejico LJ, et al. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest. 2008; 88(3):243–255. [PubMed: 18209728]
26. Massa PT, Wu C. Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J Interferon Cytokine Res. 1998; 18(7):499–507. [PubMed: 9712366]
27. Khaled AR, Buttifoski EJ, Sobel ES, Schiffenbauer J. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B. Cell Immunol. 1998; 185(1):49–58. [PubMed: 9636682]
28. Croker BA, Lawson BR, Berger M, Eidenschink C, Blasius AL, Moresco EM, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A. 2008; 105(39):15028–15033. [PubMed: 18806225]
29. David M, Chen HE, Goelz S, Larner AC, Neel BG. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol. 1995; 15(12):7050–7058. [PubMed: 8524272]
30. Massa PT, Wu C. The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells. J Immunol. 1996; 157(11):5139–5144. [PubMed: 8943425]
31. Bonaparte KL, Hudson CA, Wu C, Massa PT. Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia. Glia. 2006; 53(8):827–835. [PubMed: 16565987]
32. Hansom EM, Dickensheets H, Qu CK, Donnelly RP, Keegan AD. Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem. 2003; 278(6):3903–3911. [PubMed: 12459556]
33. Huang Z, Coleman JM, Su Y, Mann M, Rian J, Shultz LD, et al. SHP-1 regulates STAT6 phosphorylation and IL-4-mediated function in a cell type-specific manner. Cytokine. 2005; 29(3):118–124. [PubMed: 15613279]
34. Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, et al. src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest. 2003; 111(1):109–119. [PubMed: 12511594]
35. Massa PT, Saha S, Wu C, Jarosinski KW. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia. 2000; 29(4):376–385. [PubMed: 10652447]
36. Massa PT, Wu C, Fecenko-Tacka K. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. J Neurosci Res. 2004; 77(1):15–25. [PubMed: 15197735]
37. Massa PT, Ropka SL, Saha S, Fecenko KL, Beuler KL. Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus. J Virol. 2002; 76(16):8335–8346. [PubMed: 12134038]
38. Deng C, Minguela A, Hussain RZ, Radu C, Ward ES, et al. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol. 2002; 168(9):4511–4518. [PubMed: 11970996]
39. Wasserman HA, Beal CD, Zhang Y, Jiang N, Zhu C, Evavold BD. MHC variant peptide-mediated anergy of encephalitogenic T cells requires SHP-1. J Immunol. 2008; 181(10):6843–6849. [PubMed: 18981103]
40. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121–127. [PubMed: 11456302]
41. Blystone SD, Graham IL, Lindberg FP, Brown EJ. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5 beta 1. J Cell Biol. 1994; 127(4):1129–1137. [PubMed: 7525603]
42. Christophi GP, Hudson CA, Gruber R, Christophi CP, Massa PT. Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia. J Neurochem. 2008
43. Christophi GP, Isackson PJ, Blaber S, Blaber M, Rodriguez M, Scarisbrick IA. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem. 2004; 91(6):1439–1449. [PubMed: 15584920]
44. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001; 29(4):E21. [PubMed: 11160941]
45. Sun J, Ramnath RD, Tamizhsevi R, Bhatia M. Neurokinin A engages neurokinin-1 receptor to induce NF-kappaB-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. Am J Physiol Cell Physiol. 2008; 295(3):C679–C691. [PubMed: 18596216]
46. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol. 2008; 84(3):631–643. [PubMed: 18552204]
47. Kim CH, Qu CK, Hangoc G, Cooper S, Anzai N, Feng GS, et al. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med. 1999; 190(5):681–690. [PubMed: 10477552]

Lab Invest. Author manuscript; available in PMC 2010 January 01.
52. Forget G, Matte C, Siminovich KA, Rivest S, Pouliot P, Olivier M. Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1. Eur J Immunol. 2005; 35(6):1906–1917. [PubMed: 15902687]

53. Mazzone A, Ricevuti G. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica. 1995; 80(2):161–175. [PubMed: 7628754]

54. Meerschaert J, Furie MB. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol. 1995; 154(8):4099–4112. [PubMed: 7535821]

55. Mazzone A, De Servi S, Mazzucchelli I, Fossati G, Gritti D, Canale C, et al. Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: a bridge between inflammation and coagulation. Eur J Clin Invest. 1997; 27(8):648–652. [PubMed: 9279527]

56. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005; 64(8):1336–1342. [PubMed: 15851719]

57. Haque SJ, Harbor P, Tabrizi M, Yi T, Williams BR. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem. 1998; 273(51):33893–33896. [PubMed: 9852037]

58. Yetter A, Uddin S, Krolewski JJ, Jiao H, Yi T, Platianias LC. Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem. 1995; 270(31):18179–18182. [PubMed: 7629131]

59. Zhang Z, Jimi E, Bothwell AL. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. J Immunol. 2003; 171(7):3620–3626. [PubMed: 14500659]

60. Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G, Raine CS. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol. 1999; 155(5):1433–1438. [PubMed: 10550297]

61. Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J. Transcription factor NF-kappaB and inhibitor 1 kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol. 1998; 57(2):168–178. [PubMed: 9600209]

62. Zhao J, Brooks DM, Lurie DI. Lipopolysaccharide-activated SHP-1-deficient motheaten microglia release increased nitric oxide, TNF-alpha, and IL-1beta. Glia. 2006; 53(3):304–312. [PubMed: 16265671]

63. Wu L, Iwai M, Li Z, Shiuchi T, Min LJ, Cui TX, et al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol. 2004; 18(3):666–678. [PubMed: 14684844]

64. Thrall RS, Vogel SN, Evans R, Shultz LD. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am J Pathol. 1997; 151(5):1303–1310. [PubMed: 9358756]

65. An H, Hou J, Zhou J, Zhao W, Xu H, Zheng Y, et al. Phosphatase SHP-1 promotes TLR-and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol. 2008; 9(5):542–550. [PubMed: 18391954]

66. Hudson CA, Christophi GP, Cao L, Gruber RC, Massa PT. Regulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1. Neuron Glia Biol. 2006; 2(4):235–246. [PubMed: 18250891]

67. Wirsmsberger G, Hebenstreit D, Posselt G, Horejs-Hoek J, Duschl A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006; 36(7):1882–1891. [PubMed: 16810739]

68. Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2004; 149(1–2):182–186. [PubMed: 15020078]

69. Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol. 2001; 24(6):755–761. [PubMed: 11415942]
70. Richens J, Fairclough L, Ghaemmaghami AM, Mahdavi J, Shakib F, Sewell HF. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology. 2007; 212(1):29–38. [PubMed: 17270707]

71. King NE, Zimmermann N, Pope SM, Fulkerson PC, Nikolaidis NM, Mishra A, et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol. 2004; 31(3):257–265. [PubMed: 15087305]

72. Amour A, Knight CG, English WR, Webster A, Slocum PE, Knauper V, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002; 524(1–3):154–158. [PubMed: 12135759]

73. Xu L, Hilliard B, Carmody RJ, Tsabary G, Shin H, Christianson DW, et al. Arginase and autoimmune inflammation in the central nervous system. Immunology. 2003; 110(1):141–148. [PubMed: 12941151]

74. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999; 103(6):807–815. [PubMed: 10079101]

75. Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2000; 26(2):133–142. [PubMed: 10840276]

76. Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, et al. Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res. 2002; 22(6):631–640. [PubMed: 12162873]

77. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006; 112(2):195–204. [PubMed: 16733654]

78. Omari KM, John GR, Sealton SC, Raine CS. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain. 2005; 128(pt 5):1003–1015. [PubMed: 15774504]

79. Huang WX, Huang P, Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler. 2004; 10(5):482–487. [PubMed: 15471361]

80. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 1997; 17(9):5328–5337. [PubMed: 9271410]

81. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol. 1999; 163(5):2403–2409. [PubMed: 10452974]

82. Ahd KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci. 2005; 1056:218–233. [PubMed: 16387690]

83. Quinones MP, Kalkonde Y, Estrada CA, Jimenez F, Ramirez R, Mahimanathan L, et al. Role of astrocytes and chemokine systems in acute TNFalpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappaB and Akt. Mol Cell Neurosci. 2008; 37(1):96–109. [PubMed: 17949991]

84. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol. 2008; 181(6):3733–3739. [PubMed: 18768823]

85. Nguyen VT, Benveniste EN. IL-4-activated STAT-6 inhibits IFN-gamma-induced CD40 gene expression in macrophages/microglia. J Immunol. 2000; 165(11):6235–6243. [PubMed: 11086058]

86. Hamilton TA, Ohmori Y, Tebo JM, Kishore R. Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines. Pathobiology. 1999; 67(5–6):241–244. [PubMed: 10725793]
87. Major J, Fletcher JE, Hamilton TA. IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharide-stimulated mouse peritoneal macrophages. J Immunol. 2002; 168(5):2456–2463. [PubMed: 11859138]

88. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001; 167(11):6533–6544. [PubMed: 11714822]

89. Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 1995; 38(5):788–796. [PubMed: 7486871]

90. van der Goes A, Boorsma W, Hoekstra K, Montagne L, de Groot CJ, Dijkstra CD. Determination of the sequential degradation of myelin proteins by macrophages. J Neuroimmunol. 2005; 161(1–2):12–20. [PubMed: 15984939]

91. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev. 2004; 46(3):261–281. [PubMed: 15571769]

92. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004; 173(7):4692–4698. [PubMed: 15383605]

93. Wenzel J, Henze S, Worenkamper E, Basner-Tschakarjan E, Sokolowska-Wojdylo M, Steitz J, et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol. 2005; 124(6):1241–1248. [PubMed: 15955100]

94. Menzies-Gow A, Ying S, Blumberg B, Raval S, Cook SD, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002; 169(5):2712–2718. [PubMed: 12193745]

95. Scarisbrick IA. The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr Top Microbiol Immunol. 2008; 318:133–175. [PubMed: 18219817]

96. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD, et al. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci. 2002; 197(1–2):9–18. [PubMed: 11997061]

97. Kariu H, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a pro-inflammatory immune response. J Immunol. 2006; 177(6):4196–4202. [PubMed: 16951385]

98. Huang YM, Xiao BG, Ozenzi V, Kouwenhoven M, Teleshova N, Fredriksen S, et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol. 1999; 99(1):82–90. [PubMed: 10496180]

99. Link H. The cytokine storm in multiple sclerosis. Mult Scler. 1998; 4(1):12–15. [PubMed: 9532586]

100. Hermans G, Stinissen P, Hauben L, Van den Berg-Loonen E, Raus J, Zhang J. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol. 1997; 42(1):18–27. [PubMed: 9225681]

101. Rohowsky-Kochan C, Molinaro D, Cook SD. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler. 2000; 6(2):69–77. [PubMed: 10773850]

102. Ochi H, Osoegawa M, Wu XM, Minohara M, Horiuchi I, Murai H, et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci. 2002; 201(1–2):45–51. [PubMed: 12163193]

103. Ozenzi V, Kouwenhoven M, Huang YM, Kivisakk P, Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood...
cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol. 2000; 120(1):147–153. [PubMed: 10759776]

105. Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN-gamma, IL-4 and TNFalpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol. 1998; 87(1-2):27–32. [PubMed: 9670842]

106. Ishizu T, Osogawara M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005; 128(Pt 5):988–1002. [PubMed: 15743872]

107. Killestein J, Den Drijver BF, Van der Graaff WL, Polman CH, Van Lier RA. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler. 2001; 7(3):145–150. [PubMed: 11475436]

108. Christophi GP, Hudson CA, Panos M, Gruber RC, Massa PT. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol. 2009; 83(2):522–539. [PubMed: 18987138]

109. Kant AM, De P, Peng X, Yi T, Rawlings DJ, Kim JS, et al. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood. 2002; 100(5):1852–1859. [PubMed: 12176909]

110. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001; 193(7):855–862. [PubMed: 11283158]

111. Huang ZY, Hunter S, Kim MK, Indik ZK, Schreiber AD. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukoc Biol. 2003; 73(6):823–829. [PubMed: 12773515]

112. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995; 27(1):165–173. [PubMed: 7665165]

113. Tsui HW, Hasselblatt K, Martin A, Mok SC, Tsui FW. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem. 2002; 269(12):3057–3064. [PubMed: 12071971]

114. Xu Y, Banville D, Zhao HF, Zhao X, Shen SH. Transcriptional activity of the SHP-1 gene in MCF7 cells is differentially regulated by binding of NF-Y factor to two distinct CCAAT-elements. Gene. 2001; 269(1-2):141–153. [PubMed: 11376946]

115. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005; 6(5):375–387. [PubMed: 15973459]

116. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007; 357(9):851–862. [PubMed: 17660530]

117. Karpuj MV, Steinman L, Oksenberg JR. Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics. 1997; 1(1):21–28. [PubMed: 10735270]

118. Asimakopoulos FA, Hinchelwood S, Gilbert JG, Delibrias CC, Gottgens B, Fearon DT, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997; 14(10):1215–1222. [PubMed: 9121771]

119. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992; 12(2):836–846. [PubMed: 1732748]

120. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000; 157(4):1137–1146. [PubMed: 11021818]

121. Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol. 2001; 159(4):1495–1505. [PubMed: 11583976]
122. Osawa T, Chong JM, Sudo M, Sakuma K, Uozaki H, Shibahara J, et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res. 2002; 93(11):195–200.

123. Muller K, Heller H, Doerfler W. Foreign DNA integration. Genome-wide perturbations of methylation and transcription in the recipient genomes. J Biol Chem. 2001; 276(17):14271–14278. [PubMed: 11278495]

124. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB. The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A. 1988; 85(15):5693–5697. [PubMed: 2840671]

125. Mikovits JA, Young HA, Vertino P, Issa JP, Pitha PM, Turcoski-Corales S, et al. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol. 1998; 18(9):5166–5177. [PubMed: 9710601]

126. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Srira B, et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer. 2007; 121(12):2693–2702. [PubMed: 17724719]

127. Lipton HL, Liang Z, Hertzler S, Son KN. A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol. 2007; 61(6):514–523. [PubMed: 17455291]

128. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007; 67(12):5583–5586. [PubMed: 17575120]

129. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007; 67(3):946–950. [PubMed: 17283125]

130. Rouleau J, MacLeod AR, Szyf M. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem. 1995; 270(4):1595–1601. [PubMed: 7829490]

131. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylation-dependent gene silencing induced by interleukin 1 beta via nitric oxide production. J Exp Med. 1999; 190(11):1595–1604. [PubMed: 10587350]

132. Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol. 2006; 5(12):1068–1076. [PubMed: 17110288]

133. Cheng J, Kydd AR, Nakase K, Noonan KM, Murakami A, Tao H, et al. Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood. 2007; 110(6):2110–2120. [PubMed: 17540846]

134. Nakase K, Cheng J, Zhu Q, Marasco WA. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol. 2009; 85(1):165–174. [PubMed: 18948549]
The levels of several extracellular markers/adhesion molecules were quantified in macrophages of MS patients and normal subjects using flow cytometry. Macrophages of MS patients and normal subjects were stained with antibodies against A. CD14, B. CD192 (CCR2), C. CD11b (integrin αMβ2), and D. VLA-4 (integrin α4β1). The histogram overlays are labeled as follows: shaded histogram for isotype control, solid line for normal subject, and dashed line for MS patient. The levels of each antigen were quantified based on the relative Mean Fluorescence Intensity (MFI) and normalized to normal subjects represented as 1.

Figure 1.
Figure 2.
SHP-1 protein expression in macrophages of MS patients compared to normal subjects.

A. SHP-1 protein levels of MS patients and normal subjects were measured with intracellular flow cytometry. The histograms are labeled as follows: shaded histogram for isotype control, solid line for normal subject, and dashed line for MS patient.

B. SHP-1 expression was measured by flow cytometry and quantified using the Mean Fluorescence Intensity (MFI). SHP-1 levels from 24 normal subjects and 27 MS patients were normalized to average SHP-1 levels in normal subjects represented as 1.

C. Western blot analysis of SHP-1 and actin in macrophages MS patients compared to normal subjects.

D. SHP-1 protein in macrophages of MS patients and normal subjects measured by Western immunoblot was quantified by measuring the pixel density.

P = 0.001
P = 0.005
Figure 3.
SHP-1 mRNA levels in macrophages of MS patients compared to normal subjects. The absolute mRNA transcript copy numbers per 10ng of total RNA were quantified using real time RT-PCR in MS patients and normal subjects. 

A. The levels of the common SHP-1 transcript, 
B. the housekeeping gene GAPDH, 
C. the SHP-1 promoter I transcripts, and 
D. the SHP-1 promoter II transcripts were quantified with real time RT-PCR in macrophages of MS patients and normal subjects.
Figure 4.
STAT6 and STAT1 activation in macrophages of MS patients and normal subjects. Total STAT6, tyrosine phosphorylated STAT6 (pSTAT6), total STAT1, and tyrosine phosphorylated STAT1 (pSTAT1) levels in macrophages of MS patients compared to normal subjects. Macrophages of MS patients and normal subjects were fixed, permeabilized, and stained with antibodies against either against total STAT6, pSTAT6, STAT1, or pSTAT1. The histogram overlays are labeled as follows: shaded histogram for isotype control, solid line for normal subject, and dashed line for MS patient. A & B. The
levels of STAT6 and pSTAT6 were quantified based on the relative MFI in macrophages of MS patients and normal subjects before and after 1-hour treatment with IL-4. C & D. The levels of STAT1 and pSTAT1 were quantified based on the relative MFI in macrophages of MS patients and normal subjects before and after 1-hour treatment with IFN-γ.
Figure 5.
NF-κB activation in macrophages of MS patients and normal subjects. A. Macrophages from normal subjects and MS patients were treated with media alone, TNF-α or LPS for 1 hour and nuclear extracts were isolated and allowed to bind an NF-κB consensus-binding sequence. Bound NF-κB was then detected by a p65 specific antibody and quantified based on a calibration curve generated by using a purified p65 recombinant protein. The NF-κB DNA binding activity is reported as ng of bound p65 protein per 10μg of macrophage nuclear extracts. B. & C. TNF-α and IL-6 secretion was quantified in macrophages of MS patients and normal subjects. The secretion levels were significantly higher in MS patients compared to normal subjects.
patients and normal subjects. Macrophages were cultured in media alone or in the presence of the TLR ligands, LPS and dsRNA for 18 hours and supernatants were analyzed for TNF-α or IL-6 by ELISA.
Figure 6.
Gene profile of macrophages of MS patients and normal subjects. A number of genes that are STAT6-, STAT1-, or NF-κB-inducible were quantified in macrophages of normal subjects and MS patients before and after 18-hour treatment with TNF-α, IL-4, IFN-γ, and LPS. Real time RT-PCR was used to measure the mRNA levels of CCL17/TARC, CCL11/eotaxin, CXCL10/IP-10, Caspase I, CCL2/MCP-1, and Cyclooxygenase II (COX-2). The actual transcript copy number of each gene is reported in relation to the untreated normal subjects, which is designated as 1.
Figure 7.
Arginase I and iNOS expression and activity in macrophages of MS patients and normal subjects. A. Inducible Nitric Oxide Synthase (iNOS) mRNA expression was quantified in macrophages of normal subjects and MS patients before and after 18-hour treatment with TNF-α, IL-4, IFN-γ, and LPS by real-time RT-PCR. B. Similarly, the levels of nitrite, as an indicator of Nitric Oxide (NO) production, were quantified in the supernatants of macrophages from MS patients and normal subjects that were treated with TNF-α, IL-4, IFN-γ, and LPS. C. Arginase I and actin protein expression were measured in macrophages.
of MS patients compared to normal subjects by Western blot analysis. D. The enzymatic activity of arginase was quantified in macrophages of MS patients and normal subjects. E. Arginase I mRNA expression was quantified in macrophages of normal subjects and MS patients before and after 18-hour treatment with TNF-α, IL-4, IFN-γ, and LPS by real-time RT-PCR.
Figure 8.
SHP-1 was depleted in macrophages of normal subjects using siRNA and the inflammatory profile is the context of SHP-1 deficiency was characterized. A. Macrophages of normal subjects were treated with SHP-1 siRNA or control siRNA (scramble sequences) and the levels of SHP-1, arginase I, and actin protein levels were quantified by Western immunoblot analysis. In the same panel the amount SHP-1 and arginase protein measured by Western immunoblot were quantified by measuring the pixel density. Results were normalized to macrophages treated with scramble siRNA represented as 1. B. & C. Phosphorylated STAT6
(pSTAT6) and STAT1 (pSTAT1) were quantified by intracellular flow cytometry in normal subject macrophages that were treated with either SHP-1 siRNA or control siRNA. pSTAT6 and pSTAT1 were also quantified following 1 hour treatment with IL-4 or IFN-γ respectively. D.–G. Macrophages of normal subjects were pre-treated with SHP-1 siRNA or control siRNA and then treated with IL-4, LPS, IFN-γ, or TNF-α for 18hrs. The mRNA levels of CCL17/TARC, CXCL10/IP-10, and CCL2/MCP-1 were quantified by real-time RT-PCR. G. & H. TNF-α and IL-6 secretion was quantified in macrophages of normal subjects that were pre-treated with SHP-1 siRNA or control siRNA. Macrophages were cultured in media alone or in the presence of the TLR ligands, LPS and dsRNA for 18 hours and supernatants were analyzed for TNF-α or IL-6 by ELISA. I The levels of nitrite, as a indicator of Nitric Oxide (NO) production, were quantified in the supernatants of macrophages from normal subjects that were pre-treated with SHP-1 siRNA or control siRNA macrophages following treatment with TNF-α or LPS.
Table 1

Biometric data of MS patients and normal subjects used in the study

The data are shown in mean value ± SD. For the gender F stands for females and M stands for males. The age at onset of clinically diagnosed MS and disease duration are shown in years. The clinical symptoms were measured on Kurtzuke’s Expanded Disability Status Scale (EDSS) at the time the blood was drawn.

|                | Number of Subjects | Age (Years) | Gender | Age at Onset | Disease Duration | EDSS Score |
|----------------|--------------------|-------------|--------|--------------|------------------|------------|
| Normal Subjects | 24                 | 39±11       | 16F, 8M| ---          | ---              | ---        |
| MS Patients     | 27                 | 44±12       | 20F, 7M| 36±9         | 6.8±4.0          | 3.6±1.6    |